Evidence map›Paper›PMID 26382622›Full record

ArticleCancer genetics2015

Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.

Maro Ohanian, Carlos Bueso-Ramos, Chi Young Ok, Pei Lin, Keyur Patel, Mona Lisa Alattar, Joseph D Khoury, Uri Rozovski, Zeev Estrov, Yang O Huh and 2 more

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Expression of CD markers in JAK2Oncology reviews · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Maro OhanianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mohanian@mdanderson.org.
Carlos Bueso-RamosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chi Young OkDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pei LinDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Keyur PatelDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mona Lisa AlattarDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joseph D KhouryDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Uri RozovskiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zeev EstrovDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yang O HuhDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jorge CortesDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lynne V AbruzzoDepartment of Pathology, The Ohio State University, Columbus, OH, USA.
The University of Texas MD Anderson Cancer Center · USThe Ohio State University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Little is known about MYC dysregulation in myeloid malignancies, and the authors were unable to find published studies that evaluated MYC protein expression in primary cases of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Herein, we describe the clinical, morphologic, immunophenotypic, cytogenetic, and molecular genetic findings in two MDS/AML cases that contained both MYC rearrangement and the JAK2 V617F mutation. We also demonstrate MYC protein expression by immunohistochemistry in both patients.

Indexed as

AgedChromosomes, Human, Pair 14Chromosomes, Human, Pair 6Chromosomes, Human, Pair 8FemaleHumansJanus Kinase 2Leukemia, Myeloid, AcuteMaleMiddle AgedMutationMyelodysplastic SyndromesProto-Oncogene Proteins c-mycTranslocation, GeneticJAK2 protein, humanJanus Kinase 2MYC protein, humanProto-Oncogene Proteins c-mycAcute myeloid leukemiablastic plasmacytoid dendritic cell neoplasmJAK2 V617F mutationMYC

Identifiers

PMID26382622
PMCPMC4835801
OpenAlexW765297136

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.